A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
NCT06041061 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18000
Last updated 2023-09-18
Summary
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.
Conditions
- HPV InfectioN
- HPV-Related Carcinoma
Interventions
- BIOLOGICAL
-
Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell)
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the experiment vaccine
- BIOLOGICAL
-
According to the 0, 2, and 6 months immunization program, intramuscular injection of the upper arm deltoid muscle, 3 doses of the placebo
Sponsors & Collaborators
-
Guangxi Center for Disease Control and Prevention
collaborator OTHER_GOV -
Henan Center for Disease Control and Prevention
collaborator OTHER_GOV -
Sichuan Center for Disease Control and Prevention
collaborator OTHER_GOV -
Centers for Disease Control and Prevention, China
collaborator OTHER_GOV -
Yunnan Center for Disease Control and Prevention
collaborator OTHER -
Sinocelltech Ltd.
lead INDUSTRY
Principal Investigators
-
Yi Mo · Guangxi Center for Disease Control and Prevention
-
Yan Zheng · Yunnan Center for Disease Control and Prevention
-
Guohua Li · Centers for Disease Control and Prevention, China
-
Ting Huang · Sichuan Center for Disease Control and Prevention
-
Zhiqaing Xie · Henan Center for Disease Control and Prevention
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-08-13
- Primary Completion
- 2024-03-31
- Completion
- 2028-08-31
Countries
- China
Study Locations
More Related Trials
-
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
NCT05694728 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
NCT00834106 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT04083196 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT05262010 ·Status: RECRUITING ·Phase: PHASE3
-
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT03935204 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
NCT01263327 ·Status: COMPLETED ·Phase: PHASE1
-
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
NCT05056402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
NCT05371353 ·Status: RECRUITING
-
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
NCT06776055 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
NCT02888418 ·Status: UNKNOWN ·Phase: PHASE1
-
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
NCT05045755 ·Status: UNKNOWN
-
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
NCT02733068 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
NCT00294047 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent(Type 16/18 )Vaccine
NCT01735006 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
NCT03085381 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females
NCT02740777 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
NCT03900572 ·Status: COMPLETED ·Phase: PHASE1
-
3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
NCT01427777 ·Status: UNKNOWN
-
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
NCT05662020 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
NCT00306241 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years
NCT00290277 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT03676101 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04422366 ·Status: RECRUITING ·Phase: PHASE3
-
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
NCT03206255 ·Status: COMPLETED
-
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
NCT02562508 ·Status: COMPLETED ·Phase: PHASE3